Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis
Optellum has partnered with Bristol Myers Squibb (NYSE: BMY) to enhance early lung cancer diagnosis using artificial intelligence. The collaboration focuses on implementing Optellum's Virtual Nodule Clinic (VNC), the first FDA-cleared AI-powered decision support tool for early-stage lung cancer.
The platform combines Patient Discovery AI and a clinically validated Lung Cancer Prediction score to analyze CT scans and identify at-risk patients. With 93 million CT scans conducted annually in the USA, the technology enables 'opportunistic screening' through automated AI-driven analysis.
Under the agreement, Optellum will deploy its VNC platform across multiple U.S. healthcare systems to assess real-world impact and generate evidence for AI implementation best practices. The initiative aims to address the challenge of late-stage lung cancer diagnosis, which currently limits treatment options and survival rates.
Optellum ha stretto una collaborazione con Bristol Myers Squibb (NYSE: BMY) per migliorare la diagnosi precoce del cancro ai polmoni utilizzando l'intelligenza artificiale. La partnership si concentra sull'implementazione della Virtual Nodule Clinic (VNC) di Optellum, il primo strumento di supporto decisionale alimentato da IA approvato dalla FDA per il cancro polmonare in fase iniziale.
La piattaforma combina Patient Discovery AI e un punteggio di previsione del cancro ai polmoni clinicamente validato per analizzare le TAC e identificare i pazienti a rischio. Con 93 milioni di TAC eseguite ogni anno negli Stati Uniti, la tecnologia permette uno "screening opportunistico" attraverso un'analisi automatizzata guidata dall'IA.
Secondo l'accordo, Optellum implementerà la sua piattaforma VNC in diversi sistemi sanitari statunitensi per valutare l'impatto nel mondo reale e generare evidenze sulle migliori pratiche di implementazione dell'IA. L'iniziativa punta a contrastare la sfida della diagnosi tardiva del cancro ai polmoni, che attualmente limita le opzioni di trattamento e i tassi di sopravvivenza.
Optellum se ha asociado con Bristol Myers Squibb (NYSE: BMY) para mejorar el diagnóstico temprano del cáncer de pulmón mediante inteligencia artificial. La colaboración se centra en implementar la Virtual Nodule Clinic (VNC) de Optellum, la primera herramienta de apoyo a la decisión impulsada por IA aprobada por la FDA para el cáncer de pulmón en etapa temprana.
La plataforma combina Patient Discovery AI y una puntuación clínicamente validada de predicción de cáncer de pulmón para analizar tomografías computarizadas e identificar pacientes en riesgo. Con 93 millones de tomografías realizadas anualmente en EE.UU., la tecnología permite un "cribado oportunista" mediante análisis automatizado impulsado por IA.
Según el acuerdo, Optellum desplegará su plataforma VNC en varios sistemas de salud de EE.UU. para evaluar el impacto en el mundo real y generar evidencia sobre las mejores prácticas para la implementación de IA. La iniciativa busca abordar el desafío del diagnóstico tardío del cáncer de pulmón, que actualmente limita las opciones de tratamiento y las tasas de supervivencia.
Optellum은 Bristol Myers Squibb (NYSE: BMY)와 협력하여 인공지능을 활용한 폐암 조기 진단을 강화하고 있습니다. 이번 협력은 Optellum의 Virtual Nodule Clinic(VNC)을 도입하는 데 중점을 두고 있으며, 이는 FDA 승인을 받은 최초의 조기 폐암 AI 기반 의사결정 지원 도구입니다.
이 플랫폼은 Patient Discovery AI와 임상적으로 검증된 폐암 예측 점수를 결합하여 CT 스캔을 분석하고 위험 환자를 식별합니다. 미국에서 매년 9,300만 건의 CT 스캔이 이루어지는 가운데, 이 기술은 AI 자동 분석을 통한 '기회 선별검사'를 가능하게 합니다.
계약에 따라 Optellum은 미국 내 여러 의료 시스템에 VNC 플랫폼을 배포하여 실제 영향력을 평가하고 AI 도입 모범 사례에 대한 증거를 생성할 예정입니다. 이 이니셔티브는 현재 치료 옵션과 생존율을 제한하는 폐암 말기 진단 문제를 해결하는 것을 목표로 합니다.
Optellum s'est associé à Bristol Myers Squibb (NYSE: BMY) pour améliorer le diagnostic précoce du cancer du poumon grâce à l'intelligence artificielle. Cette collaboration se concentre sur la mise en œuvre de la Virtual Nodule Clinic (VNC) d'Optellum, le premier outil d'aide à la décision alimenté par l'IA approuvé par la FDA pour le cancer du poumon à un stade précoce.
La plateforme combine Patient Discovery AI et un score de prédiction du cancer du poumon cliniquement validé pour analyser les scanners CT et identifier les patients à risque. Avec 93 millions de scanners CT réalisés chaque année aux États-Unis, cette technologie permet un "dépistage opportuniste" grâce à une analyse automatisée pilotée par l'IA.
Dans le cadre de cet accord, Optellum déploiera sa plateforme VNC dans plusieurs systèmes de santé américains afin d'évaluer l'impact réel et de générer des preuves sur les meilleures pratiques d'implémentation de l'IA. L'initiative vise à relever le défi du diagnostic tardif du cancer du poumon, qui limite actuellement les options de traitement et les taux de survie.
Optellum ist eine Partnerschaft mit Bristol Myers Squibb (NYSE: BMY) eingegangen, um die Früherkennung von Lungenkrebs mithilfe von künstlicher Intelligenz zu verbessern. Der Fokus der Zusammenarbeit liegt auf der Implementierung von Optellums Virtual Nodule Clinic (VNC), dem ersten von der FDA zugelassenen KI-gestützten Entscheidungshilfetool für Lungenkrebs im Frühstadium.
Die Plattform kombiniert Patient Discovery AI und einen klinisch validierten Lung Cancer Prediction Score, um CT-Scans zu analysieren und Risikopatienten zu identifizieren. Bei jährlich 93 Millionen CT-Scans in den USA ermöglicht die Technologie ein "opportunistisches Screening" durch automatisierte KI-Analyse.
Im Rahmen der Vereinbarung wird Optellum seine VNC-Plattform in mehreren US-Gesundheitssystemen einsetzen, um die reale Wirkung zu bewerten und Evidenz für Best Practices bei der KI-Implementierung zu sammeln. Die Initiative zielt darauf ab, die Herausforderung der späten Lungenkrebsdiagnose zu bewältigen, die derzeit die Behandlungsmöglichkeiten und Überlebenschancen einschränkt.
- First FDA-cleared and CMS-reimbursed AI tool for early lung cancer diagnosis
- Access to 93 million annual CT scans for AI analysis and early detection
- Partnership enables wider implementation across U.S. healthcare systems
- 30-60% recurrence rate in Stage I-II NSCLC patients post-surgery
- Current screening programs fail to reach majority of lung cancer patients
Insights
This partnership between BMY and Optellum represents a strategic move into AI-enhanced cancer care pathways with multiple potential benefits. Optellum's FDA-cleared Virtual Nodule Clinic (VNC) could significantly improve early lung cancer detection by analyzing the 93 million CT scans already conducted annually in the US for other reasons.
The collaboration targets a critical gap in cancer care - while 30-60% of early-stage NSCLC patients experience recurrence after surgery, earlier detection could dramatically improve outcomes. BMY gains several advantages: 1) better identification of appropriate patients for their oncology therapies, 2) real-world evidence generation across multiple healthcare systems, and 3) positioning in the growing AI-healthcare intersection.
Particularly noteworthy is the platform's CMS reimbursement status, eliminating a major adoption barrier for healthcare systems. By focusing on "opportunistic screening" of existing scans rather than dedicated screening programs (which suffer from low enrollment), the approach could efficiently identify early-stage patients who would benefit most from intervention.
This builds on existing collaboration between the companies, suggesting positive preliminary results driving expanded implementation. While the immediate financial impact is modest, the long-term strategic value lies in optimizing patient journeys toward BMY's treatment options and establishing the company as a leader in AI-integrated precision oncology.
Rapidly growing lung health company aims to redefine early diagnosis and precision lung cancer care using multi-modal artificial intelligence (AI).
Lung cancer remains the leading cause of cancer-related deaths worldwide, often going undetected until it reaches an advanced stage. Late-stage diagnosis limits treatment options and reduces survival rates. While screening programs exist, they frequently fail to reach the majority of lung cancer patients due to low enrollment rates and patients not meeting eligibility criteria. However, there are 93 million Computed Tomography (CT) scans already conducted annually in the
Optellum's Virtual Nodule Clinic (VNC) is the first FDA-cleared AI-powered decision support tool for early-stage lung cancer, reimbursed by CMS and implemented by leading health systems. The platform integrates Patient Discovery AI, which utilizes Natural Language Processing to identify at-risk individuals from scan reports across healthcare systems, and a clinically validated Lung Cancer Prediction (LCP) score based on imaging AI and radiomics. This combination of AI tools enables clinicians to identify and prioritize at-risk patients for follow-up by multidisciplinary thoracic oncology teams, potentially leading to earlier intervention and improved patient outcomes.
Optellum and Bristol Myers Squibb are building on an existing research collaboration [1]. As part of this new agreement, Optellum is deploying its VNC platform at multiple healthcare systems across
"Early diagnosis is critical in improving survival rates for lung cancer patients. However,
"The agreement with Bristol Myers Squibb is a key step that helps Optellum accelerate AI-powered early diagnosis, from top academic medical centers to community centers caring for underserved patient populations who can benefit the most," commented Václav Potěšil, PhD, Optellum Founder and Chief Business Officer. "Our vision is to help drive opportunistic screening across lung cancer and other diseases – helping care teams efficiently find the right candidates for the right treatment, while augmenting their expertise so that every patient can benefit from top quality care."
[1] Nathan R Hill, Travis L Dotson, Sarah E Maus, Christina R Bellinger, Annika Rings, Lyndsey C Pickup, Noah Waterfield Price, Václav Potěšil, John R Penrod, Kevin Pollock, David P Carbone and Jasleen Pannu. "1212 Utilization of artificial intelligence support for early lung cancer diagnosis in a lung nodule program: a retrospective cohort study." Society for Immunotherapy of Cancer (2024)
About Optellum
Optellum is a commercial-stage lung health company providing artificial intelligence decision-support software that assists physicians in the early diagnosis of their patients. The company was founded so that every lung disease patient is diagnosed and optimally treated at the earliest possible stage when the probability of better health outcomes is highest. The
Media Contact
James Hounsell, james.hounsell@evolene.co.uk
View original content to download multimedia:https://www.prnewswire.com/news-releases/optellum-announces-agreement-with-bristol-myers-squibb-to-leverage-ai-to-boost-early-lung-cancer-diagnosis-302427471.html
SOURCE Optellum
FAQ
What is the main purpose of the Optellum and BMY partnership for lung cancer diagnosis?
How many CT scans are performed annually in the USA that could benefit from BMY's AI screening initiative?
What is the current recurrence rate for Stage I-II NSCLC patients after surgery?
What regulatory approvals has Optellum's Virtual Nodule Clinic received for BMY's implementation?
